Analysis of 40 Cases of Adverse Reactions to Apatinib Mesylate

doi:10.19803/j.1672-8629.2019.12.07

Abstract

Abstract: Objective To summarize the characteristics of adverse drug reactions caused by apatinib mesylate and provide data for safe and rational medication. Methods The gender, age, clinical diagnosis, history of adverse reactions, dosage, frequency of administration, organs or systems involved, clinical manifestations, time of occurrence, treatment and prognosis of adverse reactions were statistically analyzed among 40 patients with apatinib-caused adverse reactions. Results Elder males were more vulnerable to adverse reactions caused by apatinib. The main symptoms of adverse reactions included elevated blood pressure, gastrointestinal reactions, fatigue, abnormal liver function and skin lesion. There were 22 cases of mild adverse reactions and 18 cases of serious adverse reactions. Conclusion Adverse drug reactions caused by apatinib should be more effectively monitored to improve the safety of medication.

Key words: apatinib, adverse drug reaction, rational medication

CLC Number:

R994.11

ZHANG Xialan, SHEN Xikun, WU Bin. Analysis of 40 Cases of Adverse Reactions to Apatinib Mesylate[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 741-746.

References

[1] Shu T, H Q, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Science, 2011, 102(7):1374-1380.
[2] Haijun Z .Apatinib for molecular targeted therapy in tumor[J]. Drug Design, Development and Therapy, 2015, (9):6075-6081.
[3] Hu X, Cao J, Hu W, et al.Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer, 2014, 14(1):820.
[4] Li J, Qin S, Xu J, et al.Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial[J]. Journal of Clinical Oncology, 2013, 31(26):3219-3225.
[5] 李红颖, 杨翠平, 靳洪涛. 抗肿瘤药物的靶点毒性研究进展[J]. 中国药物警戒, 2018, 15(3):152-157.
[6] 左婷婷, 郑荣寿, 曾红梅,等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1):52-58.
[7] Yu M, Gao Z, Dai X, et al.Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors[J]. Clinical Pharmacokinetics, 2017, 56(1):65-76.
[8] Li J, Qin S, Xu J, et al.Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial[J]. Journal of Clinical Oncology, 2013, 31(26):3219-3225.
[9] Huang L, Wei Y, Shen S, et al.Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients[J]. Oncotarget, 2017 ,8(17):29346-29354.
[10] Liao X, Li H, Liu Z, et al.Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine (Baltimore), 2018,97(50): e13635.
[11] Miao M, Deng G, Luo S, et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].GynecolOncol, 2018, 148(2):286-290.
[12] Wang L, Liang L, Yang T, et al.A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study[J]. Medicine,2017, 96(49): e9053.
[13] Hu X, Cao J, Hu W, et al.Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer[J].BMC Cancer, 2014, 14(1):820.
[14] Lu W, Jin X L, Yang C, et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial[J].Cancer Biology & Therapy, 2017, 18(6):433-438.
[15] Li J,Qin S, Xu J, et al .Apatinib for chemotherapy-re fractory advanced metastatic gastric cancer: results from a randomized placebo-controlled, parallel-arm, phase II trial[J]. J clin Oncol,2013,31(26):3219-3225.
[16] Hu X, Zhang J, Xu B, et al.Multicenter Phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple negative breast cancer[J].International Journal of Cancer, 2014, 135(8):1961-1969.
[17] Liao X, Li H, Liu Z, et al.Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment[J]. Medicine, 2018, 97(50):e13635.
[18] Miao M, Deng G, Luo S, et al.A phase II study of apatinib in patients with recurrent epithelial ovarian cancer[J].Gynecol Oncol,2018,148(2):286-290.
[19] Wang L, Liang L, Yang T, et al.A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma[J]. Medicine, 2017, 96(49):e9053.
[20] Reddy G K, Jain V K .The Addition of Bevacizumab to FOLFOX4 Prolongs Survival in Relapsed Colorectal Cancer:Interim Data from the ECOG 3200 Trial[J]. Clinical Colorectal Cancer, 2005, 4(5):300-301.
[21] Scott A J, Messersmith W A, Jimeno A .Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs of Today, 2015, 51(4):223-239.
[22] Tian S, Quan H, Xie C, et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo[J].Cancer Science, 2011, 102(7):1374-1380.
[23] Lan CY, Wang Y, Xiong Y,et al.Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2,single-arm, prospective study. Lancet Oncol,2018,19(9):1239-1246.
[24] Bollee G, Patey N, Cazajous G, et al.Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib[J]. Nephrology Dialysis Transplantation, 2008,24(2):682-685.
[25] Li J, Qin S, Xu J, et al.Randomized, Double-Blind,Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[J]. Journal of Clinical Oncology, 2016, 34(13):1448-1454.